Literature DB >> 19548856

Cixutumumab.

Kevin P McKian1, Paul Haluska.   

Abstract

The IGF pathway plays a major role in cancer cell proliferation, survival and resistance to antineoplastic therapies in many human malignancies. As such, interference with this pathway is the target of many investigational pharmacologic agents. Cixutumumab, a monoclonal antibody to IGF-1R, utilizes this concept. In this review, we summarize preclinical, pharmacologic and early clinical data regarding this agent and discuss the impact this drug might have on the future treatment of human cancers.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19548856      PMCID： PMC2939377          DOI： 10.1517/13543780903055049

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN： 1354-3784            Impact factor:   6.206


  41 in total

1.  Biological activity of rainbow trout Ea4-peptide of the pro-insulin-like growth factor (pro-IGF)-I on promoting attachment of breast cancer cells (MDA-MB-231) via alpha2- and beta1-integrin.

Authors:  Sineenat Siri; Maria J Chen; Thomas T Chen
Journal:  J Cell Biochem       Date:  2006-12-15       Impact factor: 4.429

2.  Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.

Authors:  F E Bertrand; L S Steelman; W H Chappell; S L Abrams; J G Shelton; E R White; D L Ludwig; J A McCubrey
Journal:  Leukemia       Date:  2006-04-27       Impact factor: 11.528

3.  Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors.

Authors:  Jennifer D Wu; Kathy Haugk; Ilsa Coleman; Lillie Woodke; Robert Vessella; Peter Nelson; R Bruce Montgomery; Dale L Ludwig; Stephen R Plymate
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

4.  Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis.

Authors:  Kai-Da Wu; Li Zhou; Douglas Burtrum; Dale L Ludwig; Malcolm A S Moore
Journal:  Cancer Immunol Immunother       Date:  2006-07-11       Impact factor: 6.968

5.  Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

Authors:  X Wan; B Harkavy; N Shen; P Grohar; L J Helman
Journal:  Oncogene       Date:  2006-09-25       Impact factor: 9.867

Review 6.  IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.

Authors:  Eric K Rowinsky; Hagop Youssoufian; James R Tonra; Phillip Solomon; Douglas Burtrum; Dale L Ludwig
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

7.  Insulin-like growth factor-I receptor signaling blockade combined with radiation.

Authors:  Gregory W Allen; Corey Saba; Eric A Armstrong; Shyh-Min Huang; Sergio Benavente; Dale L Ludwig; Daniel J Hicklin; Paul M Harari
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

8.  Induction of glutathione transferase in insulin-like growth factor type I receptor-overexpressed hepatoma cells.

Authors:  Jeong Yong Lee; Chang Yeob Han; Jin Won Yang; Christopher Smith; Sang Kyum Kim; Eva Y-H P Lee; Sang Geon Kim; Keon Wook Kang
Journal:  Mol Pharmacol       Date:  2007-07-05       Impact factor: 4.436

9.  Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors.

Authors:  Paul Haluska; Heather M Shaw; Gretchen N Batzel; Donghua Yin; Julian R Molina; L Rhoda Molife; Timothy A Yap; M Luisa Roberts; Amarnath Sharma; Antonio Gualberto; Alex A Adjei; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2007-10-01       Impact factor: 12.531

10.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

Authors:  Kathryn E O'Reilly; Fredi Rojo; Qing-Bai She; David Solit; Gordon B Mills; Debra Smith; Heidi Lane; Francesco Hofmann; Daniel J Hicklin; Dale L Ludwig; Jose Baselga; Neal Rosen
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701
View more
  28 in total

1.  Trial Watch: Monoclonal antibodies in cancer therapy.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Jessica Zucman-Rossi; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

Review 2.  Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.

Authors:  Thuy Vu; Mark X Sliwkowski; Francois X Claret
Journal:  Biochim Biophys Acta       Date:  2014-07-25

3.  Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas.

Authors:  Paolo A Zucali; Iacopo Petrini; Elena Lorenzi; Maria Merino; Liang Cao; Luca Di Tommaso; Hye Seung Lee; Matteo Incarbone; Beatriz A Walter; Matteo Simonelli; Massimo Roncalli; Armando Santoro; Giuseppe Giaccone
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

4.  Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.

Authors:  Arun Rajan; Corey A Carter; Arlene Berman; Liang Cao; Ronan J Kelly; Anish Thomas; Sean Khozin; Ariel Lopez Chavez; Isabella Bergagnini; Barbara Scepura; Eva Szabo; Min-Jung Lee; Jane B Trepel; Sarah K Browne; Lindsey B Rosen; Yunkai Yu; Seth M Steinberg; Helen X Chen; Gregory J Riely; Giuseppe Giaccone
Journal:  Lancet Oncol       Date:  2014-01-15       Impact factor: 41.316

Review 5.  New treatments for bladder cancer: when will we make progress?

Authors:  Rosa Nadal; Joaquim Bellmunt
Journal:  Curr Treat Options Oncol       Date:  2014-03

Review 6.  Adverse Events and Efficacy of Cixutumumab in Phase II Clinical Trials: A systematic Review and Meta-Analysis.

Authors:  Hongxin Cao; Lixuan Cui; Wei Ma; Linhai Zhu; Kai Wang; Yang Ni; Yibing Wang; Jiajun Du
Journal:  Clin Drug Investig       Date:  2017-02       Impact factor: 2.859

Review 7.  Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Authors:  Erika Vacchelli; Jonathan Pol; Norma Bloy; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jérôme Galon; Aurélien Marabelle; Holbrook Kohrt; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

8.  Resistance to Trastuzumab in Breast Cancer.

Authors:  Paula R Pohlmann; Ingrid A Mayer; Ray Mernaugh
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

9.  Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.

Authors:  James P Dean; Cynthia C Sprenger; Junxiang Wan; Kathleen Haugk; William J Ellis; Daniel W Lin; John M Corman; Bruce L Dalkin; Elahe Mostaghel; Peter S Nelson; Pinchas Cohen; Bruce Montgomery; Stephen R Plymate
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

Review 10.  Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.

Authors:  Charles Vogel; Arlene Chan; Brunilde Gril; Sung-Bae Kim; Junichi Kurebayashi; Li Liu; Yen-Shen Lu; Hanlim Moon
Journal:  Jpn J Clin Oncol       Date:  2010-06-11       Impact factor: 3.019
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.